DataMeds AI, Inc. to acquire Helomics Corporation

DataMeds AI, Inc. has agreed to acquire Helomics Corporation in a strategic acquisition within the technology sector. The transaction was announced and completed on 11 September 2026. Both entities are based in the United States. The deal structure involves consideration through shares and loan notes. No financial value for the transaction was disclosed by either party involved in this corporate combination. This arrangement represents a direct acquisition of one technology firm by another, focusing on the operational integration of Helomics into the broader DataMeds AI business framework. The specific strategic rationale behind this move remains undisclosed in the available records.

The parties have finalised all necessary steps to close this transaction. Regulatory approvals and other customary conditions were satisfied to allow the deal to proceed to completion. As a result, Helomics Corporation is now part of the DataMeds AI portfolio. This acquisition marks a significant step for both organisations in consolidating their positions within the US technology market. The completed status indicates that all legal and financial obligations have been met. Stakeholders can expect further operational updates as the combined entity integrates its resources. The transaction stands as a fully executed corporate event with no pending conditions remaining for either side to fulfil before normal business operations continue under the new ownership structure.